Danielle Swain

Title: Innovations by Danielle Swain in Gene-Edited Natural Killer Cells

Introduction

Danielle Swain is a prominent inventor based in Cambridge, MA, known for her groundbreaking work in the field of gene editing. With a total of two patents to her name, she has made significant contributions to the development of engineered natural killer cells, which hold promise for therapeutic applications in cancer treatment.

Latest Patents

Swain's latest patents focus on engineered cells, specifically natural killer (NK) cells that have been modified through gene editing. These inventions involve cells that comprise a disrupted B2M gene and an inserted polynucleotide encoding various components, including SERPINB9 and a fusion of IL15 and IL15Rα. Additionally, the engineered cells may include modifications to other genes such as CIITA, ADAM17, FAS, CISH, and REGNASE-1. The patents also describe methods for producing these engineered cells and their potential therapeutic uses, along with guide RNA sequences targeting the described sequences.

Career Highlights

Danielle Swain is currently associated with Crispr Therapeutics AG, a company at the forefront of gene editing technology. Her work has been instrumental in advancing the understanding and application of CRISPR technology in the field of immunotherapy.

Collaborations

Swain collaborates with notable colleagues, including Valentin Sluch and Alireza Rezania, who contribute to her research and development efforts in gene editing.

Conclusion

Danielle Swain's innovative work in gene-edited natural killer cells represents a significant advancement in therapeutic strategies for cancer treatment. Her contributions continue to shape the future of gene editing and immunotherapy.